Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology

International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)

(2019) Brian T. Tsuji et al.   PHARMACOTHERAPY

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

(2019) James A. McKinnell et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vitro and in vivo activity of β-lactams in combination with novel β-lactam enhancers, zidebactam and WCK 5153, against multidrug-resistant metallo-β-lactamase producing Klebsiella pneumoniae

(2019) Bartolome Moya et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro investigation of synergy among Fosfomycin and parenteral antimicrobials against Carbapenemase-producing Enterobacteriaceae

(2019) Lindsay M. Avery et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects

(2019) Takayuki Katsube et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive paediatric Gram-negative bacteria

(2019) Phoebe C. M. Williams et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae

(2019) Matthew C. Canver et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa

(2019) Tomefa E. Asempa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

(2019) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection

(2019) Tomefa E. Asempa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales

(2019) Tomefa E. Asempa et al.   CLINICAL THERAPEUTICS

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data

(2019) Cornelius J Clancy et al.   Open Forum Infectious Diseases

In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from United States Hospitals and Comparative Activity of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes

(2018) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

(2018) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model

(2018) Kamilia Abdelraouf et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem/Cilastatin in Murine Infection Models

(2018) Mary Ann Powles et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment of Infections with OXA-48 producing Enterobacteriaceae

(2018) Adam Stewart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program, 2012 to 2015

(2018) Krystyna M. Kazmierczak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae

(2017) M. Souli et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

(2017) Juan J. Castón et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE)

(2017) Yunliang Zhang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

(2017) Latania K. Logan et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

(2017) Belén Gutiérrez-Gutiérrez et al.   LANCET INFECTIOUS DISEASES

Bloodstream infections caused byKlebsiella pneumoniaein onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey

(2016) Enrico Maria Trecarichi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency

(2016) Visanu Thamlikitkul et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-ResistantEnterobacteriaceaeBacteremia

(2016) Pranita D. Tamma et al.   CLINICAL INFECTIOUS DISEASES

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

Fosfomycin

(2016) Matthew E. Falagas et al.   CLINICAL MICROBIOLOGY REVIEWS

The rapid spread of carbapenem-resistant Enterobacteriaceae

(2016) Robert F. Potter et al.   DRUG RESISTANCE UPDATES

Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment

(2016) Takayuki Katsube et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The global epidemiology of carbapenemase-producing Enterobacteriaceae

(2016) David van Duin et al.   Virulence

Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae

(2016) Joshua T. Thaden et al.   Virulence

Aminoglycosides: An Overview

(2016) Kevin M. Krause et al.   Cold Spring Harbor Perspectives in Medicine

Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae

(2015) Jessica B. Cprek et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?

(2014) R. L. Nation et al.   CLINICAL INFECTIOUS DISEASES

Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study

(2014) M. Giannella et al.   CLINICAL MICROBIOLOGY AND INFECTION

Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae

(2013) Helen Giamarellou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens

(2013) Ana M. Sandri et al.   CLINICAL INFECTIOUS DISEASES

Fosfomycin activity versus carbapenem-resistant Enterobacteriaceae and vancomycin-resistant Enterococcus, Detroit, 2008–10

(2013) Jason M Pogue et al.   JOURNAL OF ANTIBIOTICS

Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model

(2013) T. Tangden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

(2012) Zubair A. Qureshi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality

(2012) A. Capone et al.   CLINICAL MICROBIOLOGY AND INFECTION

Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae

(2011) Abraham Borer et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae

(2011) Catharine C. Bulik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

Characterization of Ertapenem-Resistant Enterobacter cloacae in a Taiwanese University Hospital

(2011) F.-C. Yang et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides

(2010) Y. Zhou et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Characterization of a New Metallo- -Lactamase Gene, blaNDM-1, and a Novel Erythromycin Esterase Gene Carried on a Unique Genetic Structure in Klebsiella pneumoniae Sequence Type 14 from India

(2009) D. Yong et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

(2009) A. Michalopoulos et al.   CLINICAL MICROBIOLOGY AND INFECTION